...
首页> 外文期刊>Pakistan Heart Journal >CLOPIDOGREL USE - ARE WE FOLLOWING THE GUIDE LINES?
【24h】

CLOPIDOGREL USE - ARE WE FOLLOWING THE GUIDE LINES?

机译:食用油-我们是否遵循指导方针?

获取原文

摘要

Objective: To see the prescription patterns of clopidogrel in the outpatientdepartment of a tertiary care hospital. Methodology: This descriptive cross-sectional study was conducted at ArmedForces Institute of Cardiology and National Institute of Heart DiseasesRawalpindi, from 1st February 2012 to April 2012, after approval from Ethicalreview board of the institute. A structured team of MBBS doctors was created toconduct the study. Data on clopidogrel prescriptions was collected from thepharmacy where their source notes were assessed and patients takingclopidogrel were identified. Results: The study population consisted of 2263 patients. The age of patientsranged from 25 to 93 years with the mean of 60.45 years ± 9.969. The standardindications found for clopidogrel prescription included ST elevation MI (STEMI) in582 (25.7%), Non-ST elevation MI (NSTEMI) in 130 (5.7%), percutaneouscoronary interventions (PCI) in 703 (31.1 %), CABG in 300 (13.3%), stroke/TIA in60 (2.6 %) and atrial fibrillation in 15 (0.66%). These standard indicationsconstituted 79.09% of prescription. The duration of clopidogrel use ranged from1 year to maximum of 10 years with mean of 3.38 ± 2.13 years. Patients whohad suffered a NSTEMI 84.6%, and 84.3% who had suffered a STEMI more than 1year ago were still receiving clopidogrel. Conclusion: We concluded that indications for which clopidogrel wereprescribed to most patients were according to recommended internationalguidelines. But duration of its use is not according to guideline directed medicaltherapy.
机译:目的:了解三级医院门诊氯吡格雷的处方模式。方法:该描述性横断面研究在该研究所伦理审查委员会批准后,于2012年2月1日至2012年4月在ArmedForces心脏病研究所和国家心脏病研究所拉瓦尔品第进行。建立了一个由MBBS医生组成的结构化团队来进行研究。氯吡格雷处方的数据是从药房收集的,该药店评估了其原始记录并确定了服用氯吡格雷的患者。结果:研究人群包括2263名患者。患者年龄为25至93岁,平均60.45岁±9.969。氯吡格雷处方的标准适应症包括582例ST升高MI(STEMI)(25.7%),130例非ST升高MI(NSTEMI)(5.7%),703例经皮冠状动脉介入治疗(PCI)(31.1%),300例CABG( 13.3%),60例卒中/ TIA(2.6%)和15例房颤(0.66%)。这些标准适应症占处方的79.09%。氯吡格雷的使用期限为1年至最长10年,平均为3.38±2.13年。患有NSTEMI的患者为84.6%,超过1年前患有STEMI的患者为84.3%仍在接受氯吡格雷。结论:我们得出的结论是,大多数患者使用氯吡格雷的适应症均根据推荐的国际指南进行。但是,其使用期限不符合指导医学治疗的指导原则。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号